Proteasome inhibition in medaka brain induces the features of Parkinson's disease

Journal of Neurochemistry

Volumn 115, Issue 1, 2010, Pages 178-187

  Matsui, Hideaki ^a   Ito, Hidefumi ^a   Taniguchi, Yoshihito ^a,b   Inoue, Haruhisa ^a   Takeda, Shunichi ^a,b   Takahashi, Ryosuke ^a  

^a KYOTO UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

dopamine; hydroxylase; medaka (Oryzias latipes); Parkinson's disease; proteasome inhibitor; tyrosine inclusion body

Indexed keywords

EPOXOMICIN; LACTACYSTIN; PROTEASOME; PROTEASOME INHIBITOR; ACETYLCYSTEINE; ADRENERGIC RECEPTOR BLOCKING AGENT; CYSTEINE PROTEINASE INHIBITOR; DOPAMINE; NORADRENALIN; OXIDOPAMINE;

ANIMAL TISSUE; ARTICLE; BRAIN; CELL LOSS; CEREBROSPINAL FLUID; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME INHIBITION; FISH; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; BRAIN LEVEL; CELL INCLUSION; CHEMICALLY INDUCED; DRUG EFFECTS; DYSKINESIA; IMMUNOHISTOCHEMISTRY; METABOLISM; NERVE CELL; ORYZIAS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; SWIMMING; TRANSMISSION ELECTRON MICROSCOPY; UBIQUITINATION; WESTERN BLOTTING;

ORYZIAS LATIPES; ORYZIINAE; RATTUS;

ACETYLCYSTEINE; ANIMALS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; BRAIN CHEMISTRY; CYSTEINE PROTEINASE INHIBITORS; DOPAMINE; DYSKINESIA, DRUG-INDUCED; IMMUNOHISTOCHEMISTRY; INCLUSION BODIES; MICROSCOPY, ELECTRON, TRANSMISSION; NEURONS; NOREPINEPHRINE; ORYZIAS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PROTEASOME INHIBITORS; SWIMMING; SYMPATHOLYTICS; UBIQUITINATION;

EID: 77956568458     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06918.x     Document Type: Article

References (20)

1. Beal F. Lang A. (2006) The proteasomal inhibiton model of Parkinson's disease: "boon or bust"? Ann. Neurol. 60, 158 161.
2. Bedford L., Hay D., Devoy A. et al. (2008) Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J. Neurosci. 28, 8189 8198.
3. Bové J., Zhou C., Jackson-Lewis V., Taylor J., Chu Y., Rideout H. J., Wu D. C., Kordower J. H., Petrucelli L. Przedborski S. (2006) Proteasome inhibition and Parkinson's disease modeling. Ann. Neurol. 60, 260 264.
4. Cook C. Petrucelli L. (2009) A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease. Biochim. Biophys. Acta 1792, 664 675.
5. Dawson T. M. Dawson V. L. (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302, 819 822.
6. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y. Shimizu N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile Parkinsonism. Nature 392, 605 608. (Pubitemid 28207717)
7. Kordower J. H., Kannan N. M., Chu Y., Suresh Babu R., Stansell J., III., Terpstra B. T., Sortwell C. E., Steece-Collier K. Collier T. J. (2006) Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann. Neurol. 60, 264 268.
8. Leroy E., Boyer R., Auburger G. et al. (1998) The ubiquitin pathway in Parkinson's disease. Nature 395, 451 452.
9. Manning-Bò A. B., Reaney S. H., Chou V. P., Johnston L. C., McCormack A. L., Johnston J., Langston J. W. Di Monte D. A. (2006) Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann. Neurol. 60, 256 260.
10. Matsuda W., Furuta T., Nakamura K. C., Hioki H., Fujiyama F., Arai R. Kaneko T. (2009) Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J. Neurosci. 29, 444 453.
11. Matsui H., Taniguchi Y., Inoue H., Uemura K., Takeda S. Takahashi R. (2009) A chemical neurotoxin, MPTP induces Parkinson's disease like phenotype, movement disorders and persistent loss of dopamine neurons in medaka fish. Neurosci. Res. 65, 263 271.
12. Matsui H., Taniguchi Y., Inoue H., Kobayashi Y., Sakaki Y., Toyoda A., Uemura K., Kobayashi D., Takeda S. Takahashi R. (2010) Loss of PINK1 in medaka fish (Oryzias latipes) causes late-onset decrease in spontaneous movement. Neurosci. Res. 66, 151 161.
13. McNaught K. S. Olanow C. W. (2006a) Proteasome inhibitor-induced model of Parkinson's disease. Ann. Neurol. 60, 243 247.
14. McNaught K. S., Perl D. P., Brownell A. L. Olanow C. W. (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56, 149 162.
15. McNaught K. S., Jackson T., JnoBaptiste R., Kapustin A. Olanow C. W. (2006b) Proteasomal dysfunction in sporadic Parkinson's disease. Neurology 66, S37 S49.
16. Nair V. D., McNaught K. S., González-Maeso J., Sealfon S. C. Olanow C. W. (2006) p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J. Biol. Chem. 281, 39550 39560.
17. Schapira A. H., Cleeter M. W., Muddle J. R., Workman J. M., Cooper J. M. King R. H. (2006) Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann. Neurol. 60, 253 255.
18. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839 840.
19. Tofaris G. K., Razzaq A., Ghetti B., Lilley K. S. Spillantini M. G. (2003) Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem. 278, 44405 44411.
20. Zeng B. Y., Bukhatwa S., Hikima A., Rose S. Jenner P. (2006) Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann. Neurol. 60, 248 252.